Eric S White1, Meng Xia2, Susan Murray2, Rachel Dyal1, Candace M Flaherty1, Kevin R Flaherty1, Bethany B Moore1, Ling Cheng3, Tracy J Doyle4, Julian Villalba4, Paul F Dellaripa5, Ivan O Rosas4, Jonathan D Kurtis3, Fernando J Martinez6. 1. 1 Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan. 2. 2 Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan. 3. 3 Center for International Health Research, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island. 4. 4 Division of Pulmonary and Critical Care and. 5. 5 Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts; and. 6. 6 Joan and Sanford Weill Department of Internal Medicine, Weill Cornell Medical College New York, New York.
Abstract
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal interstitial lung disease (ILD) characterized by abnormal extracellular matrix (ECM) remodeling. We hypothesized that ECM remodeling might result in a plasma profile of proteins specific for IPF that could distinguish patients with IPF from other idiopathic ILDs. OBJECTIVES: To identify biomarkers that might assist in distinguishing IPF from non-IPF ILD. METHODS: We developed a panel of 35 ECM, ECM-related, and lung-specific analytes measured in plasma from 86 patients with IPF (derivation cohort) and in 63 patients with IPF (validation cohort). Comparison groups included patients with rheumatoid arthritis-associated ILD (RA-ILD; n = 33), patients with alternative idiopathic ILDs (a-ILD; n = 41), and healthy control subjects (n = 127). Univariable and multivariable logistic regression models identified biomarkers that differentiated patients with IPF from those with a-ILD. Both continuous and diagnostic threshold versions of biomarkers were considered; thresholds were chosen to maximize summed diagnostic sensitivity and specificity in univariate receiver-operating characteristic curve analysis. A diagnostic score was created from the most promising analytes. MEASUREMENTS AND MAIN RESULTS: Plasma surfactant protein (SP)-D > 31 ng/ml, matrix metalloproteinase (MMP)-7 > 1.75 ng/ml, and osteopontin > 6 ng/ml each significantly distinguished patients with IPF from patients with a-ILD, both individually and in a combined index. The odds ratio for IPF when at least one analyte in the index exceeded the threshold was 4.4 (95% confidence interval, 2.0-9.7; P = 0.0003). When at least two analytes were elevated, the odds ratio for IPF increased to 5.0 (95% confidence interval, 2.2-11.5; P = 0.0002). CONCLUSIONS: A biomarker index of SP-D, MMP-7, and osteopontin enhanced diagnostic accuracy in patients with IPF compared with those with non-IPF ILD. Our data suggest that this biomarker index may improve diagnostic confidence in IPF.
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal interstitial lung disease (ILD) characterized by abnormal extracellular matrix (ECM) remodeling. We hypothesized that ECM remodeling might result in a plasma profile of proteins specific for IPF that could distinguish patients with IPF from other idiopathic ILDs. OBJECTIVES: To identify biomarkers that might assist in distinguishing IPF from non-IPF ILD. METHODS: We developed a panel of 35 ECM, ECM-related, and lung-specific analytes measured in plasma from 86 patients with IPF (derivation cohort) and in 63 patients with IPF (validation cohort). Comparison groups included patients with rheumatoid arthritis-associated ILD (RA-ILD; n = 33), patients with alternative idiopathic ILDs (a-ILD; n = 41), and healthy control subjects (n = 127). Univariable and multivariable logistic regression models identified biomarkers that differentiated patients with IPF from those with a-ILD. Both continuous and diagnostic threshold versions of biomarkers were considered; thresholds were chosen to maximize summed diagnostic sensitivity and specificity in univariate receiver-operating characteristic curve analysis. A diagnostic score was created from the most promising analytes. MEASUREMENTS AND MAIN RESULTS: Plasma surfactant protein (SP)-D > 31 ng/ml, matrix metalloproteinase (MMP)-7 > 1.75 ng/ml, and osteopontin > 6 ng/ml each significantly distinguished patients with IPF from patients with a-ILD, both individually and in a combined index. The odds ratio for IPF when at least one analyte in the index exceeded the threshold was 4.4 (95% confidence interval, 2.0-9.7; P = 0.0003). When at least two analytes were elevated, the odds ratio for IPF increased to 5.0 (95% confidence interval, 2.2-11.5; P = 0.0002). CONCLUSIONS: A biomarker index of SP-D, MMP-7, and osteopontin enhanced diagnostic accuracy in patients with IPF compared with those with non-IPF ILD. Our data suggest that this biomarker index may improve diagnostic confidence in IPF.
Authors: M Selman; V Ruiz; S Cabrera; L Segura; R Ramírez; R Barrios; A Pardo Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-09 Impact factor: 5.464
Authors: M Thomeer; M Demedts; J Behr; R Buhl; U Costabel; C D R Flower; J Verschakelen; F Laurent; A G Nicholson; E K Verbeken; F Capron; M Sardina; G Corvasce; I Lankhorst Journal: Eur Respir J Date: 2007-12-05 Impact factor: 16.671
Authors: Charlene D Fell; Fernando J Martinez; Lyrica X Liu; Susan Murray; Meilan K Han; Ella A Kazerooni; Barry H Gross; Jeffrey Myers; William D Travis; Thomas V Colby; Galen B Toews; Kevin R Flaherty Journal: Am J Respir Crit Care Med Date: 2010-01-07 Impact factor: 21.405
Authors: José Félix Restrepo; Inmaculada del Rincón; Daniel F Battafarano; Roy W Haas; Merced Doria; Agustín Escalante Journal: Clin Rheumatol Date: 2015-08-09 Impact factor: 2.980
Authors: Matthew W Parker; Daniel Rossi; Mark Peterson; Karen Smith; Kristina Sikström; Eric S White; John E Connett; Craig A Henke; Ola Larsson; Peter B Bitterman Journal: J Clin Invest Date: 2014-03-03 Impact factor: 14.808
Authors: Emily A McDonald; Ling Cheng; Blanca Jarilla; Marianne J Sagliba; Annaliza Gonzal; Amabelle J Amoylen; Remigio Olveda; Luz Acosta; David Baylink; Eric S White; Jennifer F Friedman; Jonathan D Kurtis Journal: Infect Immun Date: 2013-10-28 Impact factor: 3.441
Authors: Ivan O Rosas; Thomas J Richards; Kazuhisa Konishi; Yingze Zhang; Kevin Gibson; Anna E Lokshin; Kathleen O Lindell; Jose Cisneros; Sandra D Macdonald; Annie Pardo; Frank Sciurba; James Dauber; Moises Selman; Bernadette R Gochuico; Naftali Kaminski Journal: PLoS Med Date: 2008-04-29 Impact factor: 11.069
Authors: Arnold S Kristof; Basil J Petrof; Qutayba Hamid; Martin Kolb; Jennifer S Landry; Alex MacKenzie; Francis X McCormack; Inga J Murawski; Joel Moss; Frank Rauch; Ivan O Rosas; Adam J Shapiro; Benjamin M Smith; David Y Thomas; Bruce C Trapnell; Lisa R Young; Maimoona A Zariwala Journal: Ann Am Thorac Soc Date: 2017-08
Authors: William D Cornwell; Cynthia Kim; Alejandra C Lastra; Chandra Dass; Sudhir Bolla; He Wang; Huaqing Zhao; Frederick V Ramsey; Nathaniel Marchetti; Thomas J Rogers; Gerard J Criner Journal: Biomarkers Date: 2018-11-19 Impact factor: 2.658
Authors: Robin R Deterding; Emily M DeBoer; Michal J Cidon; Terry E Robinson; David Warburton; Gail H Deutsch; Lisa R Young Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405
Authors: Fernando J Martinez; Alison Chisholm; Harold R Collard; Kevin R Flaherty; Jeffrey Myers; Ganesh Raghu; Simon L F Walsh; Eric S White; Luca Richeldi Journal: Lancet Respir Med Date: 2016-12-06 Impact factor: 30.700